PHI BIOMED LEADING THE FUTURE OF SMART NANOMEDICINES

HOME > R&BD > Core Technology

Core Technology

Hyaluronic Acid - Hexamethylenediamine Hydrogels
Contact Information
1 Company PHI BioMed, Korea
2 Manager Hye Ryoung Lee, MBA (aosora2001@yahoo.com)
3 Web Page http://www.phibiomed.co.kr
Researcher
4 Institute (Researcher) POSTECH (Prof. Sei Kwang Hahn)
5 Web Page http://bnl.postech.ac.kr
Technology
6 Title Hyaluronic Acid - Hexamethylenediamine Hydrogels
7 Composition Hyaluronic Acid, Hexamethylenediamine
8 Application
  • Tissue augmentation
  • Arthritic lubrication
9 Competitive Advantage
  • Highly biocompatibility and non-toxicity
  • Excellent tissue augmentation
  • Long-term lubrication effect
10 Stage of Development Preclinical
11 Data Files
  • In Vitro Degradation Tests of HA Hydrogels
  • In Vivo Pharmacokinetic Analysis
  • In Vivo Tissue Augmentation and Lubrication Tests
  • Histological Analysis after Tissue Augmentation and Lubrication
12 Test Model Drug Encapsulation of Retinoic Acid, NSAID, and MTX
13 Representative Figure [Bioconjugate Chemistry 21, 240 (2010)]
Intellectual Property
14 Domestic Patents filed/granted Patent No. 1014009070000 (2011)
15 International(PCT) Patents filed/granted US Patent 9017712.B2 (2015),
Canada Patent 2805008.A (2015),
Japanese Patent 2013519580.A (2011), etc
16 Ownership PHI BIOMED
17 Proposal Type Clinical Co-development/Licensing Out
TOP